Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | RBBP9 | O75884 | 5/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952032 | 1.00 | ALDH1A1 (0.47) | ALDH1A1FBP1RBBP9PLA2G4AMAPT | |
| SCHEMBL27596098 | 0.74 | CTSL (0.42) | ALDH1A1 | |
| SCHEMBL13237108 | 0.74 | — | — | |
| SCHEMBL2948824 | 0.74 | — | — | |
| SCHEMBL2948821 | 0.74 | — | — | |
| SCHEMBL3504222 | 0.72 | — | — | |
| SCHEMBL12832918 | 0.72 | — | — | |
| SCHEMBL2805828 | 0.70 | PDPK1 (0.44) | RBBP9PLA2G4AKMT2ASMN1; SMN2CES1 | |
| SCHEMBL2805831 | 0.70 | PDPK1 (0.44) | RBBP9PLA2G4AKMT2ASMN1; SMN2CES1 | |
| SCHEMBL201473 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763623-B2 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1976854-A2 | HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYYSLIPIDEMIA | Shering Corporation (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007087204-A2 | HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYYSLIPIDEMIA | SCHERING CORPOORATION (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070173495-A1 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173495-A1 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | GPR119, HCAR1, LDLR | ALDH1A1 2152/4885FBP1 1049/4885RBBP9 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.